CR11814A - Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica - Google Patents

Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica

Info

Publication number
CR11814A
CR11814A CR11814A CR11814A CR11814A CR 11814 A CR11814 A CR 11814A CR 11814 A CR11814 A CR 11814A CR 11814 A CR11814 A CR 11814A CR 11814 A CR11814 A CR 11814A
Authority
CR
Costa Rica
Prior art keywords
azacarbolinas
derivatives
preparation
therapeutic use
optionally substituted
Prior art date
Application number
CR11814A
Other languages
English (en)
Inventor
Arendt Christopher
Babin Didier
Bedel Olivier
Gouyon Thierry
Levit Mikhail
Mignani Serge
Moorcroft Neil
Papin David
Li Ronghua
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR11814A publication Critical patent/CR11814A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Nuevas azacarbolinas de fórmula (I), en la que:R3, R4representan independientemente el uno del otro H; hal; CF3; oxi sustituido; amida opcionalmente sustituido; amino opcionalmente sustituido; etc.
CR11814A 2008-06-12 2010-11-25 Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica CR11814A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0803262 2008-06-12

Publications (1)

Publication Number Publication Date
CR11814A true CR11814A (es) 2011-01-10

Family

ID=40445526

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11814A CR11814A (es) 2008-06-12 2010-11-25 Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica

Country Status (26)

Country Link
US (1) US20110178053A1 (es)
EP (1) EP2303882A2 (es)
JP (1) JP2011522867A (es)
KR (1) KR20110016998A (es)
CN (1) CN102124007A (es)
AR (1) AR072084A1 (es)
AU (1) AU2009259114B2 (es)
BR (1) BRPI0915204A2 (es)
CA (1) CA2725093A1 (es)
CO (1) CO6280536A2 (es)
CR (1) CR11814A (es)
DO (1) DOP2010000366A (es)
EA (1) EA018945B1 (es)
EC (1) ECSP10010670A (es)
IL (1) IL209840A0 (es)
MA (1) MA32460B1 (es)
MX (1) MX2010013699A (es)
NI (1) NI201000210A (es)
NZ (1) NZ589839A (es)
PE (1) PE20110122A1 (es)
SV (1) SV2010003754A (es)
TW (1) TW201002711A (es)
UA (1) UA101668C2 (es)
UY (1) UY31895A (es)
WO (1) WO2009150381A2 (es)
ZA (1) ZA201008387B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110365A1 (es) 2008-06-11 2011-07-11 Genentech Inc Diazacarbazoles como inhibidores de checkpoint quinasa 1 (chk1)
KR101600278B1 (ko) 2008-06-12 2016-03-08 얀센 파마슈티카 엔.브이. 히스타민 ｈ4 수용체의 다이아미노-피리딘, 피리미딘, 및 피리다진 조절제
JP2012521394A (ja) * 2009-03-24 2012-09-13 サノフイ ９ｈ−ピロロ［２，３−ｂ：５，４−ｃ’］ジピリジンアザカルボリン誘導体、この調製およびこの治療用途
FR2950891B1 (fr) * 2009-10-06 2012-11-09 Sanofi Aventis Derives d'azacarbolines 9h-pyrrolo[2,3-b:5,4-c']dipyridine, leur preparation et leur utilisation therapeutique
FR2953838B1 (fr) * 2009-12-10 2012-02-24 Sanofi Aventis Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique
US20110183938A1 (en) * 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
EP2970312B1 (en) * 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
KR101612179B1 (ko) * 2013-04-19 2016-04-12 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
CN103408573B (zh) * 2013-07-12 2015-12-23 上海工程技术大学 硼酸衍生物及其制备方法和应用
WO2018137655A1 (zh) * 2017-01-25 2018-08-02 江苏豪森药业集团有限公司 吡咯并吡啶类n-氧化衍生物及其制备方法和应用
JP7365332B2 (ja) * 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
CN116693449A (zh) 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
PE20110365A1 (es) * 2008-06-11 2011-07-11 Genentech Inc Diazacarbazoles como inhibidores de checkpoint quinasa 1 (chk1)

Also Published As

Publication number Publication date
EA201170002A1 (ru) 2011-08-30
JP2011522867A (ja) 2011-08-04
MX2010013699A (es) 2011-02-23
UA101668C2 (ru) 2013-04-25
WO2009150381A3 (fr) 2010-02-18
AU2009259114B2 (en) 2013-05-23
AR072084A1 (es) 2010-08-04
EP2303882A2 (fr) 2011-04-06
DOP2010000366A (es) 2010-12-31
EA018945B1 (ru) 2013-11-29
CO6280536A2 (es) 2011-05-20
TW201002711A (en) 2010-01-16
UY31895A (es) 2010-01-29
BRPI0915204A2 (pt) 2019-01-15
KR20110016998A (ko) 2011-02-18
WO2009150381A2 (fr) 2009-12-17
NI201000210A (es) 2011-05-09
AU2009259114A1 (en) 2009-12-17
CA2725093A1 (fr) 2009-12-17
IL209840A0 (en) 2011-02-28
ECSP10010670A (es) 2011-01-31
MA32460B1 (fr) 2011-07-03
NZ589839A (en) 2012-07-27
CN102124007A (zh) 2011-07-13
US20110178053A1 (en) 2011-07-21
PE20110122A1 (es) 2011-03-07
SV2010003754A (es) 2011-03-15
ZA201008387B (en) 2012-02-29

Similar Documents

Publication Publication Date Title
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
CR11861A (es) Compuestos organicos
SV2011003855A (es) Heteroarilos sustituidos
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
CO6331304A2 (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CR20120264A (es) Compuestos
DOP2013000212A (es) Formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparacion
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
SV2010003754A (es) Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica
SV2010003514A (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
EA201290558A1 (ru) Агонисты mglu2
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
CR20110527A (es) Derivados de 1-alquil-cinolin-4(1h)-ona, su preparación y su aplicación en terapéutica
UY30740A1 (es) Nuevo procedimiento para la preparacion de 4,4??-( 1-metil-1,2-etandilil)-bis-(2,6-piperazindiona)
ECSP11011053A (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos
NI201200103A (es) NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75
UY32448A (es) Derivados de 3-benzofuranil-indol-2-ona-3-acetamidopiperazinas sustituidos, su preparacion y su aplicacion en terapeutica
UY32447A (es) Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia
ECSP11011150A (es) Derivados de arilciclopropilacetamida útiles como activadores de glucoquinasa
CL2009000317A1 (es) Compuestos derivados de 3-alquil-piperazina sustituida; composicion farmaceutica; y su uso en el tratamiento de la depresion y ansiedad.
UA110458C2 (ru) Інгібітори ns5a вгс

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)